2-丙醇,1-(氨基氧代)-3-苯氧基-,(2R)- | 288399-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 2-丙醇,1-(氨基氧代)-3-苯氧基-,(2R)-
• 英文名称: 6,7-dichloro-4-oxo-4H-chromene-2-carboxylic acid
• 英文别名: 6,7-dichloro-4-oxochromene-2-carboxylic acid
• CAS: 288399-54-2
• 化学式: C₁₀H₄Cl₂O₄
• 分子量: 259.045
• InChiKey: YJWSRXTYWOXGTN-UHFFFAOYSA-N

物化性质

• 沸点：
  431.3±45.0 °C(Predicted)
• 密度：
  1.712±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-丙醇,1-(氨基氧代)-3-苯氧基-,(2R)- 在 氯化亚砜 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 16.0h， 以55%的产率得到4,6,7-trichlorochromen-2-one
  参考文献：
  名称：

  [EN] ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR
  [FR] ANTAGONISTES DU RECEPTEUR DE L'HORMONE DE MELANO-CONCENTRATION

  摘要：

  公开号：

  WO2003106452A3
• 作为产物：
  描述：

  3,4-二氯苯酚 在 三氯化铝 、 sodium ethanolate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 48.0h， 生成 2-丙醇,1-(氨基氧代)-3-苯氧基-,(2R)-
  参考文献：
  名称：

  Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 Antagonists:  Assessment of Potency, Efficacy, and Cardiovascular Safety

  摘要：

  Evaluation of multiple structurally distinct series of melanin concentrating hormone receptor 1 antagonists in an anesthetized rat cardiovascualar assay led to the identification of a chromone-2-carboxamide series as having excellent safety against the chosen cardiovascular endpoints at high drug concentrations in the plasma and brain. Optimization of this series led to considerable improvements in affinity, functional potency, and pharmacokinetic profile. This led to the identification of a 7-fluorochromone-2-carboxamide (22) that was orally efficacious in a diet-induced obese mouse model, retained a favorable cardiovascular profile in rat, and demonstrated dramatic improvement in effects on mean arterial pressure in our dog cardiovascular model compared to other series reported by our group. However, this analogue also led to prolongation of the QT interval in the dog that was linked to affinity for hERG channel and unexpectedly potent functional blockade of this ion channel.

  DOI：

  10.1021/jm060683e

文献信息

• Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
  申请人：Lynch K. John

  公开号：US20050209274A1

  公开（公告）日：2005-09-22

  The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

  本发明涉及式(I)的化合物，通过对抗黑素浓集激素（MCH）的作用，通过对抗黑素浓集激素受体，有助于预防或治疗进食障碍、体重增加、肥胖、生殖和性行为异常、甲状腺激素分泌、利尿和水/电解质稳态、感觉处理、记忆、睡眠、觉醒、焦虑、抑郁、癫痫、神经退行性疾病和精神障碍。
• Antagonists of melanin concentrating hormone receptor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040106645A1

  公开（公告）日：2004-06-03

  This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I: 1 where m is zero or one, n is zero to two, Y is oxygen or —N(R 9 )—, R 1 , R 2 , R 3 , R 4 , R 5 , R 9 and Ring A are defined in the specification. Coumarin and quinolone compounds where R 1 and R 2 together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.

  这项发明提供了一些与黑色素浓集激素受体-1 (MCH-R1) 相对抗的化合物。这些化合物由公式 I 表示：其中 m 为零或一，n 为零至二，Y 为氧或 —N(R9)—，R1、R2、R3、R4、R5、R9 和环 A 在说明书中有定义。偏好使用 R1 和 R2 结合形成融合苯环的香豆素和喹啉类化合物。该发明还提供了公式 VI 的化合物，其中香豆素基团被喹嗪酮环替换。这些化合物可用于治疗与 MCH-R1 相关的疾病，特别是超重症，包括肥胖症。
• Screening for Cardiovascular Safety:  A Structure−Activity Approach for Guiding Lead Selection of Melanin Concentrating Hormone Receptor 1 Antagonists
  作者：Philip R. Kym、Andrew J. Souers、Thomas J. Campbell、John K. Lynch、Andrew S. Judd、Rajesh Iyengar、Anil Vasudevan、Ju Gao、Jennifer C. Freeman、Dariusz Wodka、Mathew Mulhern、Gang Zhao、Seble H. Wagaw、James J. Napier、Sevan Brodjian、Brian D. Dayton、Regina M. Reilly、Jason A. Segreti、Ryan M. Fryer、Lee C. Preusser、Glenn A. Reinhart、Lisa Hernandez、Kennan C. Marsh、Hing L. Sham、Christine A. Collins、James S. Polakowski

  DOI：10.1021/jm0512286

  日期：2006.4.1

  An inactin-anesthetized rat cardiovascular (CV) assay was employed in a screening mode to triage multiple classes of melanin-concentrating hormone receptor I (MCHr1) antagonists. Lead identification was based on a compound profile producing high drug concentration in both plasma (> 40 mu M) and brain (> 20 mu g/g) with < 15% change in cardiovascular endpoints. As a result of these stringent requirements, lead optimization activities on multiple classes of MCHr1 antagonists were terminated. After providing evidence that the cardiovascular liabilities were not a function of MCHr1 antagonism, continued screening identified the chromone-substituted aminopiperidine amides as a class of MCHr1 antagonists that demonstrated a safe cardiovascular profile at high drug concentrations in both plasma and brain. The high incidence of adverse cardiovascular effects associated with an array of MCHrl antagonists of significant chemical diversity, combined with the stringent safety requirements for antiobesity drugs, highlight the importance of incorporating cardiovascular safety assessment early in the lead selection process.
• ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR
  申请人：ABBOTT LABORATORIES

  公开号：EP1534703A2

  公开（公告）日：2005-06-01
• US6921821B2
  申请人：——

  公开号：US6921821B2

  公开（公告）日：2005-07-26